NBIX
$152.75
Revenue | $794.9Mn |
Net Profits | $209.5Mn |
Net Profit Margins | 26.36% |
Neurocrine Biosciences Inc.’s revenue jumped 27.78% since last year same period to $794.9Mn in the Q3 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 15.62% jump in its revenue since last 3-months.
Neurocrine Biosciences Inc.’s net profit jumped 61.4% since last year same period to $209.5Mn in the Q3 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 94.88% jump in its net profits since last 3-months.
Neurocrine Biosciences Inc.’s net profit margin jumped 26.32% since last year same period to 26.36% in the Q3 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 68.55% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | 2.09 |
EPS Estimate Current Year | 2.09 |
Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current quarter stand at 2.09 - a 111.11% jump from last quarter’s estimates.
Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current year stand at 2.09.
Earning Per Share (EPS) | 0 |
Neurocrine Biosciences Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Neurocrine Biosciences Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2025-10-28 | 2.09 | 0 | -100% |
2025-05-05 | 1.09 | 0.7 | -35.78% |
2025-07-30 | 0.99 | 1.06 | 7.07% |